An open-label trial of memantine for the treatment of posttraumatic stress disorder - An open-label trial of memantine for PTSD

Kim Yoshiharu0 个研究点目标入组 20 人开始时间: 2019年3月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients diagnosed with posttraumatic stress disorder
•(2) Patients who are attending the National Center of Neurology and Psychiatry Hospital or collaborative institutes
•(3) Individuals who can understand the nature of this study and provide informed consent

•(1) Patients with duration of illness less than 6 months
•(2) Individuals who received specific psychotherapy (e.g., prolonged exposure therapy, cognitive processing therapy, and eye movement desensitization and reprocessing therapy) within 3 months prior to the recruitment into the study
•(3) Patients with comorbid schizophrenia, severe manic phase of bipolar disorder, or intellectual disability
•(4) Individuals with serious suicidal ideation
•(5) Individuals with severe physical illnesses that can interfere with study participation
•(6) Pregnant women
•(7) Individuals with the following physical conditions that are described in manufacturer's package insert as careful administration:
•-History of epilepsy or convulsion
•-Renal dysfunction
•-Factors increasing urine pH
•-Severe liver dysfunction
•(8) Patients considered unqualified for the study by their attending physicians

发起方

Kim Yoshiharu